Jun 24, 2026 08:30AM
Jun 12, 2026 05:49AM
Jun 11, 2026 03:18AM
Mar 13, 2026 01:37PM
Feb 18, 2026 06:19AM
Jan 16, 2026 12:01PM
Nov 20, 2025 08:30AM Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
Nov 17, 2025 08:30AM
Nov 10, 2025 09:31AM
Oct 27, 2025 06:33AM
Sep 30, 2025 05:23PM
Sep 30, 2025 05:23PM
Sep 30, 2025 04:16PM
Aug 11, 2025 01:20AM Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Jul 31, 2025 04:30PM
Jul 31, 2025 04:30PM
Jun 11, 2025 08:30AM
Apr 9, 2025 05:00AM
Mar 27, 2025 08:30AM
Mar 20, 2025 07:40PM
Mar 20, 2025 07:37PM Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Feb 18, 2025 09:00AM
Jan 16, 2025 04:07PM
Dec 11, 2024 09:44AM
Dec 2, 2024 04:14PM
Nov 5, 2024 07:05AM
Oct 28, 2024 04:44PM
Oct 26, 2024 07:50PM Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Sep 24, 2024 08:45AM
Sep 20, 2024 09:00AM
Sep 17, 2024 01:00PM
Aug 28, 2024 07:09AM
Aug 7, 2024 02:23PM
Aug 6, 2024 09:00AM
Jul 30, 2024 07:00AM Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
May 25, 2024 06:00AM
May 7, 2024 07:00AM
Apr 30, 2024 10:14AM
Apr 23, 2024 01:58PM
Apr 17, 2024 01:20AM
Apr 15, 2024 02:02PM
Feb 27, 2024 08:05AM Adaptimmune Therapeutics (ADAP) Appoints Cintia Piccina as Chief Commercial Officer
Feb 27, 2024 08:00AM
Feb 25, 2024 02:00PM
Feb 16, 2024 11:20AM
Feb 14, 2024 08:01AM
Feb 14, 2024 08:00AM
Feb 5, 2024 05:17PM
Feb 5, 2024 04:49PM Novartis (NVS) to acquire MorphoSys (MOR) for EUR 68 per share, EUR 2.7bn in cash
Feb 5, 2024 11:47AM

324,764 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All